Beta‑blockers after myocardial infarction and chronic coronary heart disease

Czech version

Authors: Jiří Vítovec; Jindřich Špinar; Lenka Špinarová
Authors‘ workplace: I. interní kardioangiologická klinika LF MU a FN u sv. Anny v Brně
Published in: Vnitř Lék 2022; 68(3): 178-180
Category: Review Articles

Overview

Treatment with beta-blockers has been an essential part of secondary prevention after myocardial infarction or chronic CHD for several decades. Studies that have shown a beneficial prognostically beneficial effect of beta-blockers were conducted in the period prior to the routine use of reperfusion therapy. In patients who have been treated with fibrinolytic therapy, their contribution is less pronounced. The situation is even less clear in patients who are treated with primary percutaneous coronary intervention, as prospective studies and observational data from registries do not yet give a clear view of the indications and clinical contribution of beta-blockers, especially in the group with normal ejection fraction, without signs of heart failure. Here are the latest different studies from the South Korean and Danish national registries in patients with CHD without heart failure and the effect of beta-blockers on the long-term prognosis.

Keywords:

secondary prevention – myocardial infarction – coronary heart disease – betablockers

Sources

1. Bangalore S, Makani H, Radford M et al. Clinical outcomes with β‑blockers for myocardial infarction: a metanalysis od randomized trials. Am J Med. 2014;127:939-953.

2. P. Kala, Mates M, Želízko M et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST‑segment elevation. Cor Vasa. 2017;59:e613-e644.

3. Hradec J. Kontroverze kolem betablokátorů. Vnitřní Lek. 2015;61:410-416.

4. Janský P. Léčba betablokátory u infarktu myokardu v éře primární PCI. Interv Akut Kardiol. 2019;18(2):96-98.

5. Vítovec J, Špinar J, Špinarová L. Betablokátory u kardiovaskulárních onemocnění – pro a proti. Kardiol Rev Int Med. 2019;21:86-89.

6. The Task Force for the management of acute coronary syndromes in patients presenting without persistent ST‑segment elevation of ESC. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST‑segment elevation. Eur Heart J 2020;41: doi:10.1093/eurheartj/ehaa575

7. Kim J, Kang D, Park H et al. Long‑term beta‑blocker therapy and clinical outcomes after acute myocardial infarction in patients without heart failure: nationwide cohort study. Eur Heart J. 2020;41:3521-352.

8. Sipahi I, Tuzcu EM, Wolski KE et al. Beta‑blockers and progression of coronary atherosclerosis: pooled analysis of 4 intravascular ultrasonography trials. Ann Intern Med. 2007;147:10-18.

9. Holt A, Blanche P, Zareini B, Rajan D, El‑Sheikh M, Schjerning A‑M, Schou M, Torp‑Pedersen C, McGettigan P, Gislason GH, Lamberts M. Effect of long‑term beta‑blocker treatment following myocardial infarction among stable, optimally treated patients in the reperfusion era – a Danish, nationwide cohort study. Eur Heart J. 2021;42:907-914.

10. Dargie HJ, Ford I, Fox KM. Total Ischaemic Burden European Trial (TIBET): Effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angina. Eur Heart J. 1996;17:104-112

11. Rehnqvist N, Hjemdahl R, Billing E et al. Treatment of stable angina pectoris with calcium antagonists and ß‑blockers. The APSIS study. Angina Prognosis Study in Stockholm. Cardiologia. 1995;40(12 Suppl 1):301.

12. von Arnim T. Medical treatment to reduce total ischemic burden: Total Ischemic Burden Bisoprolol Study (TIBBS), a multicenter trial comparing bisoprolol and nifedipine. The TIBBS Investigators. J Am Coll Cardiol. 1995;25:231-238

13. van Diepen S, Armstrong PW. Learning whether to subtract beta‑blockers: it’s about time. Europ Heart J. 2021;42:915-918